Arcus Biosciences Shares Surge 88.2% While 2026 Loss Estimate Narrows
Over the past six months, Arcus Biosciences stock has climbed 88.2%, outperforming the biotech sector’s 22.4% gain. Consensus 2026 loss-per-share estimates have narrowed from $3.90 to $3.86 over the past 60 days, and the company maintains a Zacks Rank #2.
1. Stock Performance
Arcus Biosciences stock has soared 88.2% over the past six months, well above the industry’s 22.4% gain. The strong rally reflects market optimism about the company’s pipeline and recent investor sentiment shifts.
2. EPS Estimate Revisions
Over the last 60 days, analysts have trimmed the 2026 loss-per-share forecast from $3.90 to $3.86, signaling growing confidence in expense management and future cost controls. Narrower loss estimates may reduce downside risk ahead of key pipeline readouts.
3. Zacks Ranking and Peer Context
Arcus Biosciences holds a Zacks Rank #2 (Buy), placing it among top-rated biotech names. Its performance and estimate revisions contrast with peers Castle Biosciences and ANI Pharmaceuticals, underscoring differentiated investor expectations.